Study of CT-0525 Doses First Patient With a Solid Tumor Overexpressing HER2
May 20th 2024The first patient has been given CT-0525, a first-in-class, ex vivo gene-modified autologous CAR-monocyte cellular therapy, in a phase 1 trial of the agent for those with HER2-overexpressing solid tumors.
Read More
FDA Expands HT-001 Trial to Include Cancers With EGFR-Associated Toxicities
January 18th 2024Following clearance from the FDA, Hoth Therapeutics is carrying out a clinical trial as part of its open investigational new drug program for HT-001 in cancers undergoing toxicities from EGFR inhibition.
Read More